Yahalom Vered, Ellis Martin H, Poole Joyce, Rahimi-Levene Naomi, Shinar Eilat, DaCosta Yehudit, Manny Noga, Levene Cyril
National Blood Group Reference Laboratory, Magen David Adom, Tel Hashomer, Israel.
Transfusion. 2002 Feb;42(2):247-50. doi: 10.1046/j.1537-2995.2002.00019.x.
Lu6 is a high-incidence antigen of the Lutheran blood group. Examples of anti-Lu6 are rare and are of uncertain clinical significance.
Three patients were encountered in whom anti-Lu6 was detected on pretransfusion screening. The patients were all Iranian Jews and were not known to be related. In vitro studies to ascertain the potential clinical significance of the antibody using the monocyte monolayer assay (MMA) were negative in two patients. The third patient received a two-unit transfusion of incompatible Lu6 RBCs with no signs of hemolysis. However, after the transfusion, the MMA and a chemiluminescence test were positive, whereas a chromium survival study was normal. Thus, the antibody may have changed in its clinical significance.
Although anti-Lu6 does not appear to be a clinically significant RBC antibody in all circumstances, transfusion of Lu6 RBCs in patients with anti-Lu6 should be performed cautiously.
Lu6是路德血型的一种高发生率抗原。抗-Lu6的例子罕见，其临床意义尚不确定。
在3例患者的输血前筛查中检测到抗-Lu6。这些患者均为伊朗犹太人，且彼此无亲缘关系。使用单核细胞单层试验（MMA）确定该抗体潜在临床意义的体外研究，在2例患者中呈阴性。第3例患者输注了2单位不相容的Lu6红细胞，未出现溶血迹象。然而，输血后，MMA和化学发光试验呈阳性，而铬红细胞存活研究结果正常。因此，该抗体的临床意义可能已发生变化。
尽管抗-Lu6在所有情况下似乎并非具有临床意义的红细胞抗体，但对于有抗-Lu6的患者，输注Lu6红细胞仍应谨慎进行。
